Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA3 | P07451 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA6 | P23280 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL22610188 | 0.91 | ALOX15 (0.48) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28721775 | 0.83 | ALOX15 (0.43) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11025532 | 0.83 | ALOX15 (0.51) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL707209 | 0.83 | ALOX15 (0.58) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4384670 | 0.77 | HSD17B10 (0.56) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL204727 | 0.77 | ALOX15 (0.64) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6954737 | 0.76 | ALOX15 (0.58) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1800353 | 0.76 | TDP1 (0.48) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15022038 | 0.75 | TDP1 (0.52) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1685055 | 0.75 | HSD17B10 (0.61) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538169-B2 | Ion conductive film and fuel cell using the same | KABUSHIKI KAISHA TOSHIBA (JP) | 2009-05-26 | — | — | US | claimed |
| EP-1275121-B1 | CORROSION-PROTECTED COAXIAL CABLE AND METHOD OF MAKING SAME | COMMSCOPE INC (US) | 2008-03-12 | — | — | EP | claimed |
| US-12268680-B2 | Compositions and methods for treating cancer | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240335449-A1 | COMBINATION THERAPY FOR VAV3 CANCER | CHILDREN'S HOSPITAL MEDICAL CENTER | 2024-10-10 | — | — | US | disclosed |
| EP-4384170-A1 | COMBINATION THERAPY WITH AN IODVA1 COMPOUND FOR THE TREATMENT OF VAV3 CANCER | Children's Hospital Medical Center (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20230129271-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CHILDREN'S HOSPITAL MEDICAL CENTER | 2023-04-27 | — | — | US | disclosed |
| WO-2023018688-A1 | COMBINATION THERAPY WITH AN IODVA1 COMPOUND FOR THE TREATMENT OF VAV3 CANCER | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-02-16 | — | — | WO | disclosed |
| US-11564913-B2 | Compositions and methods for treating cancer | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-01-31 | — | — | US | disclosed |
| CN-114858947-A | Detection method of alpha-dicarbonyl compound and application thereof | 湖南师范大学 | 2022-08-05 | — | — | CN | disclosed |
| EP-3962896-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Children's Hospital Medical Center (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-114072385-A | Compositions and methods for treating cancer | 儿童医院医学中心 | 2022-02-18 | — | — | CN | disclosed |
| WO-1994020304-A1 | IMPROVED INK-RECEPTIVE SHEET | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-09-15 | — | — | WO | disclosed |
| US-5342688-A | Contains at least one polymeric mordant with a guanidine functionality | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-08-30 | — | — | US | disclosed |
| EP-0310808-A1 | Curable compositions and corrosion resistant coatings prepared therefrom | AMERICAN CYANAMID COMPANY (US) | 1989-04-12 | — | — | EP | disclosed |
| US-4778728-A | AMINE-REACTIVE POLYMER OF (METH)ACRYLAMAIDOGLYCOLATE, POLYFUNCTIONAL AMINE CROSSLINKER, BENZOTRIAZOLE OR A DIPYRIDYL | AMERICAN CYANAMID COMPANY (US) | 1988-10-18 | — | — | US | disclosed |
| EP-0152091-A2 | Method for improving the selective inhibition of the activity of human pancreatic and salivary amylase and an inhibitor preparation therefore | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1985-08-21 | — | — | EP | disclosed |
| US-4159898-A | Alkyl-guanidino-heterocyclic compounds, their manufacture and use as additives for fuels and lubricants | INSTITUT FRANCAIS DU PETROLE (FR) | 1979-07-03 | — | — | US | disclosed |
| US-4113637-A | DISPERSANTS, DETERGENTS | INSTITUT FRANCAIS DU PETROLE (FR) | 1978-09-12 | — | — | US | disclosed |
| US-4071459-A | Alkyl-guanidino-heterocyclic compounds, their manufacture and use as additives for fuels and lubricants | INSTITUT FRANCAIS DU PETROLE (FR) | 1978-01-31 | — | — | US | disclosed |
| US-3935314-A | Anti-hypertensive compositions of benzimidazole derivatives | BEECHAM GROUP LIMITED (EN) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335449-A1 | COMBINATION THERAPY FOR VAV3 CANCER | VAV1, ABL1, BCR | ALOX15 3584/4885HSD17B10 3025/4885CYP1A2 3579/4885 |
| US-11564913-B2 | Compositions and methods for treating cancer | HRAS, ING2, KRAS | ALOX15 2530/4885HSD17B10 4113/4885CYP1A2 1415/4885 |
| US-20230129271-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HRAS, ING2, KRAS | ALOX15 2530/4885HSD17B10 4113/4885CYP1A2 1415/4885 |
| US-12268680-B2 | Compositions and methods for treating cancer | HRAS, ING2, KRAS | ALOX15 2530/4885HSD17B10 4113/4885CYP1A2 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.